Facing steep competition, Novo Nordisk has slashed the price for its weight loss drug Wegovy — temporarily, at least.

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

An inexpensive pill for treating HIV could become an alternative to injections for diabetic eye disease, a small study ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...